Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Or...
October 09 2019 - 7:00AM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
announces that results from the single agent dose-escalation
portion of the ongoing Phase 1 study of AG-270 in patients with
MTAP-deleted tumors and the pre-clinical translational research
supporting combination strategies have been accepted for
presentation at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics being held October 26 –
30, 2019 in Boston. AG-270 is an investigational, first-in-class
methionine adenosyltransferase 2a (MAT2A) inhibitor.
The schedule for the presentations is as follows:
Title: A Phase 1 trial of AG-270 in patients
with advanced solid tumors or lymphoma with homozygous MTAP
deletionOral Date & Time: Sunday, October 27,
2019, 11:50 a.m. – 12:20 p.m. ETOral Session:
Spotlight on Proffered Papers 1Oral Location:
Level 3, Ballroom ABPoster Date & Time:
Monday, October 28, 2019, 12:30 p.m. – 4:00 p.m. ETPoster
Session: Poster Session B: New Molecular
TargetsPoster Location: Level 2, Hall
DAbstract: B116Presenter: Rebecca
Suk Heist, M.D., Massachusetts General Hospital
Title: Mitotic defects induced by MAT2A
inhibitors guides translational drug combination strategies with
AG-270 and taxanesPoster Date & Time: Monday,
October 28, 2019, 12:30 p.m. – 4:00 p.m. ETPoster
Session: Poster Session B: New Molecular
TargetsPoster Location: Level 2, Hall
DAbstract: B115Presenter: Peter
Kalev, Ph.D., Agios Pharmaceuticals
Conference Call InformationAgios will host an
investor event on October 27, 2019 at 6:30 p.m. ET in Boston to
review the AG-270 Phase 1 dose-escalation data and pre-clinical
research. The event will be webcast live and can be accessed under
"Events & Presentations" in the Investors and Media section of
the company's website at www.agios.com. The archived webcast will
be available on the company's website beginning approximately two
hours after the event.
About Agios Agios is focused on discovering and
developing novel investigational medicines to treat cancer and rare
genetic diseases through scientific leadership in the field of
cellular metabolism and adjacent areas of biology. In addition to
an active research and discovery pipeline across both therapeutic
areas, Agios has two approved oncology precision medicines and
multiple first-in-class investigational therapies in clinical
and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website
at www.agios.com.
About Agios/Celgene CollaborationAG-270 is part
of our 2016 global research collaboration agreement with Celgene
Corporation focused on metabolic immuno-oncology. Celgene has the
option to participate in a worldwide 50/50 cost and profit share
with Agios, under which Agios is eligible for up to $169 million in
clinical and regulatory milestone payments for the program.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of AG-270; Agios’ plans regarding
future data presentations; and the potential benefit of its
strategic plans and focus. The words “anticipate,” “expect,”
“intend,” “potential,” “milestone,” “goal,” “will,” “on track,”
“upcoming,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from Agios'
current expectations and beliefs. For example, there can be no
guarantee that any product candidate Agios or its collaborators is
developing will successfully commence or complete necessary
preclinical and clinical development phases, or that development of
any of Agios' product candidates will successfully continue.
Moreover, there can be no guarantee that the two approved oncology
precision medicines being commercialized by Agios and its
collaborators will receive commercial acceptance. There can be no
guarantee that any positive developments in Agios' business will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other important factors, including: Agios' results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios' ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media Contact: Holly Manning,
617-844-6630 Associate Director, Investor Relations
Holly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024